By Cecilia Butini 
 

Novartis AG said Thursday that it has signed a new agreement with BioNTech SE to support the production of the company's and Pfizer Inc.'s Covid-19 vaccine at one of its facilities.

The Swiss pharma major said it will support the fill-and-finish operations of the vaccine, meaning the transfer of the vaccine substance into vials under sterile conditions.

It will do so at its facility in Ljubljana, Slovenia, and will begin operations in the first half of 2022, Novartis said. At least 24 million vaccine doses will be filled there, the company said.

The agreement follows another one which was signed earlier this year and which had Novartis filling and finishing more than 50 million doses at its site in Stein, Switzerland.

 

Write to Cecilia Butini at cecilia.butini@wsj.com

 

(END) Dow Jones Newswires

October 21, 2021 01:43 ET (05:43 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Novartis Charts.
Novartis (NYSE:NVS)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Novartis Charts.